TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16208799

Group type: EXPERIMENTAL
Intervention: Oral‐B ProfessionalCare 7000 (PC 7000)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Crest SpinBrush Pro (SBP)
Number of subjects: 70
Study: 12439787

Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg daily for three months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg continued for another nine months with medroxyprogesterone for ten days every three months
Number of subjects: 51
Study: 10080612

Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m2, 30-minute infusion daily for 5 days every 21 days)
Number of subjects: 211

Group type: COMPARATOR
Intervention: CAV (cyclophosphamide 1,000 mg/m2, doxorubicin 45 mg/m2, vincristine 2 mg, infused on day 1 every 21 days)
Number of subjects: 211
Study: 7742676

Group type: EXPERIMENTAL
Intervention: Health checks performed by nurses in primary care
Number of subjects: 2205
Study: 2248508

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for eight weeks (2 mg/kg/day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for twelve weeks (2 mg/kg/day)
Number of subjects: 73
Study: 7002163

Group type: COMPARATOR
Intervention: Fenbufen
Number of subjects: 3457
Study: 31847536

Group type: EXPERIMENTAL
Intervention: Varenicline (smoking cessation treatment)
Number of subjects: 179
Study: 30675926

Group type: EXPERIMENTAL
Intervention: Inspection and polypectomy during both insertion and withdrawal
Number of subjects: 421

Group type: COMPARATOR
Intervention: Inspection and polypectomy entirely during withdrawal
Number of subjects: 421
Study: 28105737

Group type: EXPERIMENTAL
Intervention: Twice-daily tooth brushing with a rotating-oscillating power toothbrush (Oral-B Professional Care 1000™)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (UC) by caregivers
Number of subjects: 54
Study: 25779774

Group type: EXPERIMENTAL
Intervention: Los Angeles Fast-Food Ban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft drink consumption
Number of subjects: 0
Study: 23466649

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF), 300 mg orally per day
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 21097811

Group type: EXPERIMENTAL
Intervention: Testing for C trachomatis by means of a sample obtained at home and mailed to the laboratory
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 4000
Study: 19740418

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 428

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 428
Study: 17099526

Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reamed intramedullary nailing
Number of subjects: 18
Study: 15682845

Group type: EXPERIMENTAL
Intervention: Intravenous regional blockade therapy consisting of dexamethasone and lidocaine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (11 healthy subjects)
Number of subjects: 26
Study: 11417025

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 2

Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 2
Study: 9582556

Group type: EXPERIMENTAL
Intervention: Oral daily calcitriol 0.5 micrograms/die (Treatment A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Three oral boluses of 2 micrograms of calcitriol a week (Treatment B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single oral bolus of 2 micrograms of calcitriol a week (Treatment C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (15 patients, mean age 47 +/- 12 years, creatinine clearances of 21 +/- 12 ml/min)
Number of subjects: 16
Study: 7812699

Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy (IS) using iodine‐131 anti‐carcinoembryonic antigen (CEA) and anti‐carbohydrate 19‐9 (CA 19-9) monoclonal antibody
Number of subjects: 17

Group type: COMPARATOR
Intervention: Computed tomography (CT-scan)
Number of subjects: 17
Study: 3046584

Group type: EXPERIMENTAL
Intervention: Cavitron Biotronics tonometer
Number of subjects: 75

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 75
Study: 30845365

Group type: EXPERIMENTAL
Intervention: Alendronic acid 70 mg once weekly (n=215)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo (n=206)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Alendronic acid
Number of subjects: 421
Study: 30427494

Group type: EXPERIMENTAL
Intervention: 40% mangosteen peel extract gel (MP-40)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No treatment (negative-control)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bleaching + no treatment (positive-control)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate (SA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 10% mangosteen peel extract gel (MP-10)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 20% mangosteen peel extract gel (MP-20)
Number of subjects: 150
Study: 26657597

Group type: EXPERIMENTAL
Intervention: Olanzapine combined with psychosocial interventions
Number of subjects: 1154
Study: 25326508

Group type: EXPERIMENTAL
Intervention: Implicit-positive-age-stereotype-intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Explicit-positive-age-stereotype-intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined implicit- and explicit-positive-age-stereotype-intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 22924334

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (n = 211)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Assessment-only control (n = 194)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Low-risk drinkers (n = 102)
Number of subjects: 598
Study: 20426604

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Music therapy
Number of subjects: 101
Study: 18062165

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 24
Study: 16131892

Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub and isopropyl alcohol paint (Group 2)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Povidone‐iodine scrub and paint (Group 1)
Number of subjects: 127
Study: 10646148

Group type: EXPERIMENTAL
Intervention: Nikon Retinomax handheld autorefractor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nikon Retinomax handheld autorefractor under cycloplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nikon Retinomax handheld autorefractor without cycloplegia
Number of subjects: 0
Study: 9301413

Group type: EXPERIMENTAL
Intervention: n-3 enriched foods (EPA and DHA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control foods (unenriched)
Number of subjects: 9
Study: 8112481

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 0
Study: 3772925

Group type: EXPERIMENTAL
Intervention: Professional-taught 12-h arthritis self-management courses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lay-taught 12-h arthritis self-management courses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 3045027

Group type: EXPERIMENTAL
Intervention: 10 mg of cisapride i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study: 31868130

Group type: EXPERIMENTAL
Intervention: Lycra sleeve plus rehabilitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Only-rehabilitation group
Number of subjects: 20
Study: 28853979

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 27
Study: 28505994

Group type: EXPERIMENTAL
Intervention: Spine Balance 3D system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bridge exercise
Number of subjects: 24
Study: 25872776

Group type: EXPERIMENTAL
Intervention: Prophylactic manual rotation
Number of subjects: 254

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 254
Study: 23505166

Group type: EXPERIMENTAL
Intervention: Different criteria for accelerometry data reduction
Number of subjects: 2240
Study: 21091877

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/day for up to 34 weeks
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 514
Study: 19409710

Group type: EXPERIMENTAL
Intervention: Follicular phase (n=21)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Luteal phase (n=17)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Craving at wake-up
Number of subjects: 38
Study: 16267603

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg in the morning, placebo at bedtime
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg at bedtime, placebo in the morning
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (glucose) in the morning, amitriptyline 25 mg at bedtime
Number of subjects: 15
Study: 15573829

Group type: EXPERIMENTAL
Intervention: Aerobic and strength exercise
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (normal living)
Number of subjects: 95
Study: 11549985

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 188

Group type: COMPARATOR
Intervention: Betaxolol 0.25%
Number of subjects: 188
Study: 9219471

Group type: EXPERIMENTAL
Intervention: Capiox E oxygenator with nonpulsatile (NP) blood pump
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Capiox E oxygenator with pulsatile (PP) blood pump
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Capiox E oxygenator (both PP and NP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Maxima and Ultrox oxygenators
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Maxima oxygenator
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ultrox oxygenator
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Capiox E oxygenator
Number of subjects: 90
Study: 8354978

Group type: EXPERIMENTAL
Intervention: Surgery or percutaneous transluminal renal angioplasty (PTRA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Renal artery stenosis (RAS) patients
Number of subjects: 81

Group type: COMPARATOR
Intervention: Patients with severe hypertension lacking significant renal artery stenosis
Number of subjects: 81
Study: 3304951

Group type: EXPERIMENTAL
Intervention: Cyclandelate at a dosage of 1600 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30794622

Group type: EXPERIMENTAL
Intervention: Best ESRF prediction model including age, gender, eGFR and albuminuria
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Addition of ethnicity to the prediction model
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Follow-up period
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Incident ESRF
Number of subjects: 1970
Study: 28498501

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 30
Study: 24289224

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg BID
Number of subjects: 197
Study: 24035327

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CCRT) with fluorouracil (5‐FU) plus mitomycin
Number of subjects: 620
Study: 21346001

Group type: EXPERIMENTAL
Intervention: Dopamine agonist pergolide given orally
Number of subjects: 24
Study: 18434638

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 176
Study: 16271818

Group type: EXPERIMENTAL
Intervention: Instructions with a hint
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instructions without a hint
Number of subjects: 0
Study: 12582754

Group type: EXPERIMENTAL
Intervention: Low-pressure (LP) pneumoperitoneum (7 mmHg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard-pressure (SP) pneumoperitoneum (12 mmHg)
Number of subjects: 148
Study: 11220553

Group type: EXPERIMENTAL
Intervention: Sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, maintained at 20 mg through week 24)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 175
Study: 9123738

Group type: EXPERIMENTAL
Intervention: Neoadjuvant combination therapy with flutamide and LHRH agonist for 3 months before radical prostatectomy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 161
Study: 8473453

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (0.75 mg for two doses 12 h apart)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Yuzpe regimen
Number of subjects: 834
Study: 3768488

Group type: EXPERIMENTAL
Intervention: Citrate salt of naftidrofuryl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxalate salt of naftidrofuryl
Number of subjects: 0
Study: 29533154

Group type: EXPERIMENTAL
Intervention: Patient-centered care transition intervention (n = 85)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Enhanced usual care control (n = 86)
Number of subjects: 171
Study: 27245783

Group type: EXPERIMENTAL
Intervention: Intratympanic lidocaine and dexamethasone (ITLD) injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intratympanic saline injection (Control)
Number of subjects: 40
Study: 24723218

Group type: EXPERIMENTAL
Intervention: Group art therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 140
Study: 22745140

Group type: EXPERIMENTAL
Intervention: Curcuminoid (30 mg 3 times daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diclofenac sodium (25 mg 3 times daily)
Number of subjects: 80
Study: 19119067

Group type: EXPERIMENTAL
Intervention: Interval swimming at S(200-400) (1.28±0.05 m/s)
Number of subjects: 12
Study: 18087561

Group type: EXPERIMENTAL
Intervention: Intensive glycemic and lipid control
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 116

Group type: COMPARATOR
Intervention: No statins
Number of subjects: 116
Study: 15814551

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporin-ME
Number of subjects: 205

Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 205
Study: 12405240

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9849102

Group type: EXPERIMENTAL
Intervention: System Responsiveness (SR) with a focus on Standard Deviation of System Responsiveness (SDSR) above 82 ms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Placement tasks requiring visual feedback
Number of subjects: 33
Study: 8205863

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 2684384

Group type: EXPERIMENTAL
Intervention: Mitoguazone (MGBG)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vinblastine (VLB)
Number of subjects: 52
Study: 4415722

Group type: EXPERIMENTAL
Intervention: High Disinhibitors
Number of subjects: 49

Group type: COMPARATOR
Intervention: Low Disinhibitors
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Disinhibition subscale of the SSS
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Other subscales of the SSS
Number of subjects: 49
Study: 31099215

Group type: EXPERIMENTAL
Intervention: Electroacupuncture nerve stimulation therapy (ENST), 50 min per session, three times a week for 3 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Perfusion therapy of four‐medication combination (heparin sodium, lidocaine, sodium bicarbonate, gentamicin sulfate), twice a week for the first 6‐8 weeks, then twice per month for 3 months
Number of subjects: 68
Study: 28530451

Group type: EXPERIMENTAL
Intervention: High-Volume Injection (HVI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 26698295

Group type: EXPERIMENTAL
Intervention: Antiobesity advertisements emphasizing individual responsibility
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Images of overweight individuals
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Images of fast food
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Stigmatizing images of overweight individuals
Number of subjects: 162
Study: 24451221

Group type: EXPERIMENTAL
Intervention: Self-reported IBD diagnosis
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported disease location for Crohn's disease
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported presence of perianal disease for Crohn's disease
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported disease behavior for Crohn's disease
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported disease location for ulcerative colitis
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported history of bowel surgery for Crohn's disease
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported history of bowel surgery for ulcerative colitis
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported current pouch or ostomy for Crohn's disease
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self-reported current pouch or ostomy for ulcerative colitis
Number of subjects: 450
Study: 22348468

Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil supplement (250 mg DHA/d and 60 mg EPA/d)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil supplement
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 420
Study: 20947710

Group type: EXPERIMENTAL
Intervention: Double poling at low intensity (∼53% Vo(2peak))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Double poling at high intensity (∼74% Vo(2peak))
Number of subjects: 8
Study: 17629042

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) at 0, 2, and 6 weeks, then every 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methylprednisolone (0.8-1 mg/kg daily for 3 weeks, then tapering)
Number of subjects: 24
Study: 16266385

Group type: EXPERIMENTAL
Intervention: Nasal budesonide (100 microg per nostril)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 32
Study: 11904593

Group type: EXPERIMENTAL
Intervention: Self-sampling methods (swabs and tampons)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Clinician-directed sampling (speculum sampling)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Self-sampling methods (2 sequential swabs)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Self-sampling methods
Number of subjects: 103
Study: 10935831

Group type: EXPERIMENTAL
Intervention: Reduced glutathione (GSH) 600 mg intramuscularly for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Symptomatic therapies for 12 weeks
Number of subjects: 32
Study: 8548221

Group type: EXPERIMENTAL
Intervention: Subtotal colectomy
Number of subjects: 91

Group type: COMPARATOR
Intervention: On-table irrigation and segmental colectomy
Number of subjects: 91
Study: 2021388

Group type: EXPERIMENTAL
Intervention: High-dose intramuscular triamcinolone (360 mg over the first three days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-dose oral prednisone (median dose 12.5 mg per day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose intramuscular triamcinolone
Number of subjects: 12
Study: 6302831

Group type: EXPERIMENTAL
Intervention: pivmecillinam 200 mg t.i.d. for 1 week
Number of subjects: 15
Study: 31806543

Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg) subcutaneously every 3-4 weeks for about 6 months, then every 12 weeks for a total duration of 5 years.
Number of subjects: 4509

Group type: COMPARATOR
Intervention: Placebo subcutaneously every 3-4 weeks for about 6 months, then every 12 weeks for a total duration of 5 years.
Number of subjects: 4509

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 4509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4509
Study: 31329023

Group type: EXPERIMENTAL
Intervention: Dual-factor gradual self-control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-controlled task difficulty group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-controlled feedback group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Yoked conditions (control)
Number of subjects: 60
Study: 28270286

Group type: EXPERIMENTAL
Intervention: Third-generation dual-source CT scanner (collimation of 2×192×0.6 mm, rotation time of 0.25 s)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Second-generation dual-source CT scanner (collimation of 2×128×0.6 mm, rotation time of 0.28 s)
Number of subjects: 59
Study: 26265678

Group type: EXPERIMENTAL
Intervention: Birth weight (BW) for estimating UVC insertion depth
Number of subjects: 188

Group type: COMPARATOR
Intervention: Shoulder-umbilicus length for estimating UVC insertion depth
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Birth weight (BW) for estimating UAC insertion depth
Number of subjects: 188

Group type: COMPARATOR
Intervention: Shoulder-umbilicus length for estimating UAC insertion depth
Number of subjects: 188
Study: 26634615

Group type: EXPERIMENTAL
Intervention: ICG-guided antihypertensive therapy
Number of subjects: 272

Group type: COMPARATOR
Intervention: Empiric antihypertensive therapy
Number of subjects: 272
Study: 23663796

Group type: EXPERIMENTAL
Intervention: 30‐min lumbar massage by a physiotherapist during the active phase of labour
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (physiotherapist only answered questions)
Number of subjects: 46
Study: 22005661

Group type: EXPERIMENTAL
Intervention: Subepineural injection at the neural bifurcation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Separate postbifurcation injections around the tibial and peroneal nerves
Number of subjects: 50
Study: 19126874

Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD) 6 g in drinks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD) 6 g in solid foods
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo drinks and foods (control)
Number of subjects: 37